What is Johnson & Johnson’s (JNJ) Economic Moat, and is it Widening or Narrowing?

Johnson & Johnson (NYSE:JNJ) closed at $264.74 on September 30, almost 43% higher than a year ago and within a few percent of its record.

The company is worth about $638 billion and turns 29.19% of its $97.93 billion in revenue into operating profit.

READ ALSO: Johnson & Johnson (JNJ) Taps Sail Biomedicines in Bid for CAR-T Edge Over Bristol Myers Squibb

Johnson & Johnson’s Real Asset is its Ability to Keep Producing Drugs:

Individual drugs are not the asset. The ability to keep producing them is. Johnson & Johnson runs research, trials, approval, and global distribution at a scale very few companies match. Each of those is a barrier on its own. A promising molecule from a small biotech still needs all four to reach patients, which is why licensing deals with larger firms are so common.

The medical device business adds a second, different moat. Hospitals buy systems rather than individual items, and the company describes those relationships as long-term contracts rather than repeat orders. Changing supplier is closer to a retraining exercise than a purchasing decision.

The returns confirm something durable is at work. Return on equity reaches 25.74%, and free cash flow ran to $16.89 billion over the past twelve months.

Revenue also grew 6.60% last quarter, which is respectable for a company approaching $100 billion of annual sales.

DON’T MISS: Could Icotyde Become Johnson & Johnson’s Next Blockbuster in China?

Patent Expiries and Talc Litigation Both Keep Running:

An economic moat is whatever stops a competitor from taking your customers. In pharmaceuticals, it usually means a patent, and every patent has an expiry date written into it.

Patents grant a monopoly for a fixed period, and when that ends, generic manufacturers take the volume quickly. The research machine has to replace that revenue continuously, which is why the pipeline matters more than any drug currently selling.

Icotyde is the current test of that. On September 29, Bank of America raised its peak sales estimate for the oral psoriasis treatment to $4.5 billion, from $2.4 billion previously.

Litigation is the second pressure, and it is unusual in its scale here. Johnson & Johnson has spent years managing talc claims, and exposure of that duration is a call on senior management time as well as on the balance sheet. Neither cost appears cleanly in the reported numbers.

The balance sheet carries $49.04 billion of debt, comfortably serviced by the cash the business produces.

The valuation is the part that has changed most. After a rise of more than 45%, the shares trade near 31 times trailing earnings, but only about 21 times what analysts forecast for next year.

That gap is large, and the likeliest explanation is that trailing earnings are depressed by charges rather than that profit is about to jump by half. Investors who bought this company for its dividend and its stability now hold it after a gain of more than 40%, on a yield of 2.02%.

At roughly 21 times next year’s estimates, they are paying for the moat to hold rather than to widen.

Conclusion:

What Johnson & Johnson owns is the ability to keep producing drugs rather than any drug in particular, and the device business adds switching costs that pharmaceuticals never have. On that basis, the moat is holding. However, it is a moat racing a calendar. Every patent expires on a schedule no competitive position can alter, and the talc litigation continues to absorb attention that would otherwise go to the pipeline. A gain of more than 40% has also removed most of the discount the shares once carried.

Market Sentiment:

Johnson & Johnson was held by 117 hedge funds with a combined stake value of about $10.2 billion at the end of Q2 2026 in the Insider Monkey database. This is up from 113 hedge fund holders in the previous quarter, although the value of those positions slipped from around $10.3 billion.

READ NEXT: What is Charles Schwab’s (SCHW) Economic Moat, and is it Widening or Narrowing? and Amgen (AMGN) Sells its Deerfield Campus for $151 Million and Leases it Back

This article is originally published at Insider Monkey.